Aptarion Biotech AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.aptarion.com
Clinical Trials
4
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Aptarion Biotech AG
- Target Recruit Count
- 150
- Registration Number
- NCT05962606
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, Germany
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪Clinique Saint Pierre, Ottignies, Belgium
Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects.
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Aptarion Biotech AG
- Target Recruit Count
- 16
- Registration Number
- NCT05343819
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Intravenous AON-D21Drug: Intravenous placebo
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Aptarion Biotech AG
- Target Recruit Count
- 40
- Registration Number
- NCT05018403
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
News
No news found